Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile NTRK1 fusion
Therapy Larotrectinib
Indication/Tumor Type congenital fibrosarcoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NTRK1 fusion congenital fibrosarcoma sensitive Larotrectinib Clinical Study - Cohort Actionable In a retrospective study (EPI VITRAKVI), Vitrakvi (Larotrectinib) treatment in patients with infantile fibrosarcoma harboring an NTRK fusion resulted in an objective response rate of 90.2%, disease control rate of 100%, and an 80% decreased likelihood of a medical treatment failure event (7.8% vs 35.7%, HR=0.20, P=0.0060) compared to chemotherapy-based treatment (PMID: 38657345; NCT05236257). 38657345
PubMed Id Reference Title Details
(38657345) Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study). Full reference...